Research map: Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery

Back to the article

Papers in this map

  1. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer · Christof Vulsteke · 2026 · 103 citations · Cited by this paper
  2. Re: Matthew D. Galsky and Andrea Necchi. Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.07.014 · Pietro Scilipoti · 2026 · Cites this paper
  3. Urolithiasis in patients with cancer · 2026 · Related
  4. 17 Evaluation of Safety of Preoperative GLP-1 Receptor Agonists in Patients Undergoingelective Surgery: A Systematic Review, Meta-Analysis and Meta-Regression · Sivesh Kathir Kamarajah · 2025 · 28 citations · Cited by this paper
  5. Bladder cancer research is blossoming in Birmingham · 2026 · Related
  6. Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center · Francesco Pellegrino · 2024 · 24 citations · Cited by this paper
  7. Animal models of spinal cord injury in neuro-urological research · 2026 · Related
  8. Obesity and Complication Risk From Radical Cystectomy: Identifying a Body Mass Index Threshold · Louise Catherine McLoughlin · 2022 · 16 citations · Cited by this paper
  9. Transitional urology: a comprehensive review of the transitional care process · 2026 · Related
  10. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study · Andrea Necchi · 2026 · 15 citations · Cited by this paper
  11. Why counting women is not enough: from inclusion to equity in oncology trials · 2026 · Related
  12. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer · Matt D. Galsky · 2026 · 13 citations · Cited by this paper
  13. Polypropylene mesh degradation and systemic disease: biological plausibility is not clinical evidence · 2026 · Related
  14. Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients · Jakob Kohler · 2026 · 2 citations · Cited by this paper
  15. Leveraging generative AI to enhance doctor–patient communication · 2026 · Related
  16. Optimizing local control in the surgical management of bladder cancer · Martin Egger · 2025 · 1 citation · Cited by this paper
  17. Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial · Andrea Necchi · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)